의약품 블리스터 시장 : 세계 예측(2026-2032년)

The Medicine Blister Market is projected to grow by USD 3.98 billion at a CAGR of 6.50% by 2032.

Medicine Blister Packaging: Executive Overview

Medicine blister packaging consists of formed cavities sealed with lidding material to protect individual doses. Its relevance is tied to dose integrity, product traceability, patient adherence, portability, and compatibility with automated pharmaceutical packaging lines. Industry priorities increasingly center on barrier performance, child resistance, senior-friendly opening, recyclable structures, and reliable high-speed production.

Packaging Priorities Are Shifting from Protection to Lifecycle Performance

The landscape is changing as pharmaceutical manufacturers balance product protection with material efficiency, regulatory expectations, usability, and end-of-life considerations. Demand for improved moisture, oxygen, light, and tamper barriers is accompanied by greater attention to downgauging, mono-material designs, recycled-content compatibility, and separation of mixed materials where feasible. Serialization, anti-counterfeiting features, and connected packaging are also strengthening the role of blisters in supply-chain assurance and patient engagement.

Artificial Intelligence Improves Quality, Planning, and Patient-Centric Design

Artificial intelligence is being applied across blister operations to identify seal defects, cavity-forming inconsistencies, print errors, contamination, and missing doses through machine vision. Predictive models can support maintenance scheduling, process-parameter optimization, demand planning, and deviation analysis. In design and human-factors work, AI can help evaluate opening force, readability, layout, and adherence-oriented instructions, while human oversight remains essential for validation, data governance, and regulated decision-making.

Regional Insights: Regulation and Healthcare Access Shape Blister Adoption

North America emphasizes compliance, child-resistant formats, serialization, and efficient contract packaging. Latin America is influenced by medicine affordability, local manufacturing, distribution reliability, and the need for robust packaging in varied climates. Europe places strong emphasis on patient safety, sustainability, recycling policy, and harmonized pharmaceutical requirements. The Middle East is shaped by imported medicines, centralized procurement, temperature-sensitive distribution, and premium quality expectations. Africa presents diverse needs linked to healthcare access, anti-counterfeiting, supply-chain resilience, and climate protection. Asia-Pacific combines large pharmaceutical production bases, expanding healthcare access, export-oriented manufacturing, and rapid adoption of automation and digital traceability.

Group Insights: Trade, Regulation, and Supply-Chain Coordination Matter

ASEAN markets benefit from regional manufacturing links while retaining varied regulatory and infrastructure conditions. BRICS economies combine substantial pharmaceutical demand and production capabilities with differing standards, reimbursement environments, and domestic-content priorities. The European Union is shaped by coordinated medicine-safety requirements, sustainability initiatives, and cross-border supply chains. G7 countries generally prioritize advanced quality systems, patient-centric usability, and environmental performance. GCC markets emphasize import reliability, centralized purchasing, climate resilience, and medicine authenticity. NATO members span diverse packaging ecosystems but share strong interest in secure medical supply chains, interoperability, and continuity of essential medicines.

Country Insights: Local Requirements Define Packaging Decisions

Australia emphasizes regulated quality, remote distribution resilience, and accessible labeling. Brazil combines a large domestic pharmaceutical system with localization, affordability, and anti-counterfeiting priorities. Canada focuses on bilingual communication, safety, and dependable distribution across a wide geography. China is advancing domestic pharmaceutical capability, automation, traceability, and sustainability. France and Germany prioritize European compliance, recycling performance, and engineering quality. India combines high-volume medicine production with affordability, adherence, and protection against humidity and counterfeiting. Italy and Spain reflect European safety and sustainability requirements alongside established pharmaceutical manufacturing. Japan emphasizes precision, reliability, elderly usability, and highly controlled production. Mexico is shaped by domestic and export manufacturing, climate protection, and supply-chain security. Russia faces complex sourcing and distribution considerations alongside pharmaceutical self-reliance objectives. South Korea combines advanced manufacturing, automation, and serialization capabilities. The United Kingdom emphasizes medicine safety, packaging usability, environmental responsibility, and resilient procurement. The United States prioritizes child resistance, serialization, quality assurance, adherence support, and efficient automated packaging.

Actions for Leaders: Build Resilient, Compliant, and Lower-Impact Blister Systems

Leaders should segment packaging designs by medicine sensitivity, patient population, distribution climate, and regulatory pathway rather than pursuing a single universal format. They should qualify multiple sources for critical films, foils, tooling, and machinery; strengthen incoming-material controls; and use validated vision inspection, seal testing, and serialization. Sustainability programs should assess full lifecycle performance, including barrier trade-offs, recyclability infrastructure, material reduction, and patient safety. Investments in AI should begin with high-value, measurable use cases and include validated datasets, audit trails, cybersecurity, and operator accountability. Finally, human-factors testing should guide opening force, readability, dose organization, and accessibility across age groups.

Research Methodology: Evidence-Led Assessment of Medicine Blister Packaging

This executive summary uses a structured qualitative assessment of the medicine blister packaging landscape. The approach organizes evidence around packaging functions, pharmaceutical manufacturing practices, regulatory and sustainability pressures, digital quality systems, regional conditions, economic groupings, and country-level operating environments. Insights are synthesized comparatively across the required geographies, with emphasis on recurring drivers, constraints, and implementation priorities. No market estimates, market shares, forecasts, or company-specific claims are used.

Conclusion: Blister Packaging Is Becoming a Strategic Pharmaceutical Capability

Medicine blister packaging is evolving from a protective container into an integrated component of pharmaceutical quality, adherence, authentication, and supply-chain resilience. The strongest strategies will combine validated barrier performance with patient-centered usability, traceability, automation, and credible environmental improvements. Regional and country conditions require adaptable designs, qualified supply networks, and disciplined regulatory execution. Organizations that connect packaging engineering with data, operations, procurement, and patient needs will be better positioned to deliver safe and dependable medicines.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Medicine Blister Market, by Product Type

• 7.1. Introduction
• 7.2. Hard Gel Capsules
• 7.3. Soft Gel Capsules
• 7.4. Tablets
  • 7.4.1. Chewable Tablets
  • 7.4.2. Dispersible Tablets
  • 7.4.3. Film Coated Tablets
  • 7.4.4. Sugar Coated Tablets
• 7.5. Unit Dose

8. Medicine Blister Market, by Material Type

• 8.1. Introduction
• 8.2. Alu PVC
• 8.3. PVC
• 8.4. PVDC Coated PVC

9. Medicine Blister Market, by Machine Type

• 9.1. Introduction
• 9.2. Cold Forming
  • 9.2.1. Continuous Cold Forming
  • 9.2.2. Rotary Cold Forming
• 9.3. Thermoforming
  • 9.3.1. Intermittent Machines
  • 9.3.2. Rotary Machines

10. Medicine Blister Market, by Application

• 10.1. Introduction
• 10.2. Over The Counter
  • 10.2.1. Pain Relievers
  • 10.2.2. Self Care Supplements
• 10.3. Prescription
  • 10.3.1. Acute Medication
  • 10.3.2. Chronic Medication

11. Medicine Blister Market, by End User

• 11.1. Introduction
• 11.2. Contract Packaging Service Providers
  • 11.2.1. Integrated Service Providers
  • 11.2.2. Specialized Service Providers
• 11.3. Pharmaceutical Manufacturers
  • 11.3.1. Large Pharmaceutical Companies
  • 11.3.2. Small And Medium Enterprises

12. Medicine Blister Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Medicine Blister Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Medicine Blister Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. ACG Worldwide Pvt. Ltd.
• 16.2. Amcor plc
• 16.3. Berry Global Group, Inc.
• 16.4. Constantia Flexibles Group GmbH
• 16.5. Essentra plc
• 16.6. Gerresheimer AG
• 16.7. Huhtamaki Oyj
• 16.8. IMA S.p.A.
• 16.9. Klockner Pentaplast Group
• 16.10. Marchesini Group S.p.A.
• 16.11. Perlen Packaging AG
• 16.12. Rohrer Corporation
• 16.13. Sonoco Products Company
• 16.14. Syntegon Technology GmbH
• 16.15. Tekni-Plex, Inc.
• 16.16. Uhlmann Packaging Systems GmbH
• 16.17. WestRock Company

17. Key Experts